PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials

Background: Small Cell Lung Cancer (SCLC) is a neuroendocrine carcinoma characterized by aggressive behavior and poor prognosis with limited treatment options. Poly ADP-Ribose Polymerase inhibitors (PARPi) are novel anti-cancer agents that induce DNA damages and cause cell death in tumor cells with...

Full description

Saved in:

Bibliographic Details
Main Authors:	Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, Brigitta Cindy Lauren
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Cancer Treatment and Research Communications
Subjects:	PARPi Small-cell lung cancer Efficacy Adverse event
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468294225000127
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
by: Amir Sheikholeslami, et al.
Published: (2024-09-01)

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)

Clinical Significance of the Peripheral Blood Neutrophil-to-Lymphocyte Ratio in Predicting Chemotherapy Outcomes for Small Cell Lung Cancer
by: Gao L, et al.
Published: (2025-01-01)

Klinefelter syndrome diagnosed at autopsy and small-cell lung carcinoma
by: Haruyasu Sakuranaka, et al.
Published: (2025-01-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro
by: Liu Rui, et al.
Published: (2023-06-01)

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy
by: Nao Kobayashi, et al.
Published: (2025-01-01)

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01)

Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review
by: Rencui Quan, et al.
Published: (2025-01-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data
by: Fabrizio Nelli, et al.
Published: (2025-01-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival
by: Yunming Tao, et al.
Published: (2025-01-01)

Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials
by: Andrea Messori, et al.
Published: (2025-01-01)

Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
by: Saloni Mangal, et al.
Published: (2024-12-01)

Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks
by: Mingming Tan, et al.
Published: (2025-01-01)

The Relationship of Sirtuin 1 and Sirtuin 2 Expression with Clinicopathological Parameters in Non Small-Cell Lung Carcinomas
by: Fatma Cakmak Kazanci, et al.
Published: (2024-11-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Association of whole grain food consumption with lung cancer risk: a prospective cohort study
by: Kanran Wang, et al.
Published: (2025-01-01)

The role of radiotherapy in small cell lung cancer: a new paradigm for the radiation oncologist
by: Paolo Borghetti, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context
by: Jiacheng Yao, et al.
Published: (2025-03-01)

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
by: Maximilian Riedel, et al.
Published: (2025-01-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
by: Yifan Wang, et al.
Published: (2025-01-01)

The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer
by: Guomin Gu, et al.
Published: (2024-12-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Composition of the sputum bacterial microbiome of patients with different pathomorphological forms of non-small-cell lung cancer
by: V. G. Druzhinin, et al.
Published: (2024-04-01)

Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics
by: Negar Alizadeh, et al.
Published: (2025-01-01)

The effect of the relative dose intensity of chemoradiotherapy on the effectiveness of therapy of locally advanced unresectable non-small cell lung cancer
by: A. E. Glukhareva, et al.
Published: (2024-03-01)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Machine learning insights into early mortality risks for small cell lung cancer patients post-chemotherapy
by: Min Liang, et al.
Published: (2025-01-01)

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy
by: Hohyung Nam, et al.
Published: (2025-01-01)